硕腾 2024年度报告

Nurturing the world andhumankind by advancingcare for animals 2024 Financial Highlights *Revenue charts by species, product category andmarket exclude revenues associated with Client SupplyServices and Human Health, which represented 1% oftotal 2024 revenue. †Adjusted net income and its components and adjusteddiluted earnings per share (non-GAAP financialmeasures) are defined as reportednet income attributable to Zoetis and reporteddiluted earnings per share, excludingpurchase accounting adjustments, acquisition anddivestiture-related costs, and certain significant items. ‡Represents operational growth (a non-GAAP financialmeasure), which is defined as growth excluding theimpact of foreign exchange. Reported revenue growth,including the impact of foreign exchange, was 4% for2022, 6% for 2023 and 8% for 2024. Revenue Net Income Attributable to ZoetisAdjusted Net Income Attributable to Zoetis†Diluted Earnings Per ShareAdjusted Diluted Earnings Per Share†Net Cash Provided by Operating ActivitiesResearch & Development ExpenseCapital Expenditures A MESSAGE FROM CHIEF EXECUTIVE OFFICER KRISTIN PECK Dear Shareholders, Purpose, resilience, and a passion for animalhealth drove Zoetis to deliver one of our mostsuccessful years ever—in the face of complexconditions around the world. Cementing our position at the forefront of the essential and durableanimal health industry, in 2024 we grew revenue 11% operationally‡andadjusted net income†by 15% operationally and returned more than $2.6billion to shareholders—an increase of over $800 million versus 2023.Delivering 8% average annual operational revenue growth since our InitialPublic Offering in 2013—3 points above the industry average—Zoetis isdriving sustainable growth through our unique model of innovation andcommercial excellence. In 2024, we expanded our product portfolio withmore than 100 geographic expansions and nearly 20 enhancements;introduced groundbreaking animal health solutions; met evolvingcustomer needs; and strengthened our collaborations with stakeholdersworldwide. Our dedicated colleagues make all the difference in our success atZoetis—bringing to life our purpose of nurturing the world and humankindby advancing care for animals. This year’s report highlights our effortsto meet the evolving needs of animals, customers, communities, and ourcontributions to a more sustainable world through notable achievements. Full Speed Ahead: Advancing our 6 Strategic Priorities In livestock, we expanded the reachof our innovations through regulatoryapprovals in markets such as Brazil forValcor®, a prescription endectocide forthe treatment and control of internal andexternal parasites in cattle; the U.K. forProtivity®, the first modified live vaccineto offer protection against MycoplasmaBovis in healthy cattle; and in Canada forAlpha Ject Micro® 7 ISA, a combinationvaccine for Atlantic Salmon, now enhancedwith protection against Infectious SalmonAnemia Virus. 1. Lead Through InnovationAcross Our Diverse Portfolio This included an agreement to purchase amanufacturing site in Melbourne, Australia,and the expansion of our distribution centerin Lee’s Summit, Missouri, USA, positioningus to ensure a long-term supply of productsfor customers. Continued growth of our osteoarthritis (OA)pain therapies and ongoing success in ourdermatology and parasiticides franchisesare a testament to our ability to identifyunmet needs, create new categoriesand standards of care, and innovateand compete in existing areas with newtreatments and vaccines. We also expanded our diagnostics toolswith the addition of AI urine sedimentanalysis for ourVetscan Imagyst®platformand the launch ofVetscan OptiCell™,offering AI-powered complete blood countanalysis to enable advanced hematologyinsights. Our OA pain franchise, consisting ofLibrela®for dogs andSolensia®for cats,is changing the quality of life for pets andpet owners and represents a new standardof care in veterinary medicine. Additionalinnovations for dogs included new claimsforSimparica Trio®in Canada and the U.S.for prevention against Asian longhorn tickinfestation (Haemaphysalis Iongicornis)and the approval in China forApoquel®Chewable, the first and only chewabletreatment for the control of allergic itch andinflammation in dogs. 2. Deliver an ExceptionalExperience to Delight OurCustomers Deepening our commitment to customers,we established a Global Medical Affairsteam to provide comprehensive medicalsupport, education and training across theproduct lifecycle. This fosters engagementamong medical professionals and drivesglobal strategies for clinical studies,education and partnerships with keyopinion leaders. In 2024, we expanded and enhancedmanufacturing and distribution facilitiesand diagnostics capabilities to best meetcustomers’ needs for innovative animalhealth solutions. 3. Power Our Business ThroughDigital Solutions and DataInsights Through responsible use of digitaltechnologies and data insights, we arerevoluti